Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 328.00
Bid: 325.50
Ask: 330.00
Change: 28.00 (9.33%)
Spread: 4.50 (1.382%)
Open: 304.00
High: 350.00
Low: 303.00
Prev. Close: 300.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Oxford BioMedica adds former Teva exec to board

Thu, 15th Jul 2021 14:54

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and Thursday and not separately reported by Alliance News:

----------

Mitchells & Butlers PLC - Birmingham, England-based operator of pubs, bars and restaurants - Says non-executive directors Colin Rutherford and Imelda Walsh will step down from the board on Monday next week, while Ron Robson will depart as a non-executive director on July 31. Mitchells & Butlers had announced the three departures back in May as part of a reduction in the size of its board to nine members.

----------

Salt Lake Potash Ltd - Western Australia-focused organic sulphate of potash miner - Hires Stuart Fraser as chief financial officer. Fraser most recently was chief accounting officer at oil field services firm Weatherford International, having previously worked for peer Schlumberger.

----------

Oxford BioMedica PLC - Oxford, England-based gene and cell therapy company - Hires Michael Hayden as non-executive director, starting Thursday. Hayden is a Canadian who has founded five biotechnology companies and also served as president of Global R&D & chief scientific officer at Israel-based Teva Pharmaceuticals Industries Ltd from 2012 to 2017.

----------

Everyman Media Group PLC - operates fourth largest cinema chain in UK by number of venues - Hires Maggie Todd as independent non-executive director, effective immediately. Todd was vice president of Communications for Walt Disney Studios Motion Pictures in Europe for 12 years. She also worked at Twenty Century Fox.

----------

BMO Capital & Income Investment Trust PLC - investment trust with portfolio consisting mainly of FTSE All-Share companies - Senior Independent Director Clare Dobie retires, having served on the board since 2012. Tim Scholefield appointed senior independent director in her place.

----------

Troy Income & Growth Trust PLC - invests predominantly in UK equities - Hires Brigid Sutcliffe as non-executive director, starting August 1. Sutcliffe is a chartered accounting who worked in investment banking and as a management consultant. Jann Brown will retire from the board in January, having served for nine years, and Sutcliffe will take over as chair of the Audit Committee at that time.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 Apr 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 08:19

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Read more
6 Apr 2021 08:08

Oxford Biomedica strikes three-year deal with Boehringer Ingelheim

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.

Read more
6 Apr 2021 07:53

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

Read more
21 Mar 2021 20:57

EU rebuffs UK calls to ship AstraZeneca COVID vaccines from Europe

By Francesco GuarascioBRUSSELS, March 21 (Reuters) - The European Union is rebuffing British government calls to ship AstraZeneca COVID-19 vaccines produced in a factory in the Netherlands, an EU official said on Sunday.Former EU member Britain ha...

Read more
19 Mar 2021 10:29

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Read more
19 Mar 2021 07:50

Oxford Biomedica says Sanofi pulling out of haemophilia project

(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.

Read more
3 Feb 2021 13:56

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

Read more
29 Jan 2021 09:11

UPDATE 1-EU holds out for more after AstraZeneca offered 8 mln extra COVID-19 shots

* Astra had committed to at least 80 mln shots in Q1* EU funded two UK plants under deal with Astra - sources* Astra says UK has priority for doses produced there (Adds detail, background)By Francesco Guarascio and Sabine SieboldBRUSSELS, Jan 29 (Re...

Read more
18 Jan 2021 17:18

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

Read more
8 Jan 2021 09:40

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

Read more
8 Dec 2020 12:31

UK's initial AstraZeneca shots will come from Europe, taskforce says

By Alistair SmoutLONDON, Dec 8 (Reuters) - Britain's initial doses of the COVID-19 vaccine candidate developed by AstraZeneca and Oxford University will come from Europe rather than a domestic supply chain, the country's Vaccine Taskforce said.The...

Read more
1 Dec 2020 14:29

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

Read more
9 Nov 2020 10:01

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Read more
9 Nov 2020 09:16

Oxford Biomedica strikes collaboration agreement with PhoreMost

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has inked a discovery collaboration agreement with UK-based biopharmaceutical company PhoreMost.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.